Stromal expression of SPARC in pancreatic adenocarcinoma

Cancer and Metastasis Reviews

Volumn 32, Issue 3-4, 2013, Pages 585-602

  Neuzillet, Cindy ^a   Tijeras Raballand, Annemilaï ^b   Cros, Jérôme ^a   Faivre, Sandrine ^a   Hammel, Pascal ^a   Raymond, Eric ^a  

^a BEAUJON HOSPITAL   (France)

^b AAREC Filia Research   (France)

Author keywords

EMT; Extracellular matrix; Nab paclitaxel; Pancreatic adenocarcinoma; Pancreatic cancer; SPARC

Indexed keywords

GEMCITABINE; MATRIX METALLOPROTEINASE; OSTEONECTIN; PACLITAXEL; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; CANCER INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; INOPERABLE CANCER; METASTASIS; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TUMOR INVASION;

ADENOCARCINOMA; ALBUMINS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION; HUMANS; OSTEONECTIN; PACLITAXEL; PANCREATIC NEOPLASMS; PROGNOSIS; STROMAL CELLS;

EID: 84889637206     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-013-9439-3     Document Type: Review

References (123)

1. Siegel, R., Naishadham, D., & Jemal, A. (2013). Cancer statistics, 2013. CA: A Cancer Journal for Clinicians, 63(1), 11-30. doi: 10.3322/caac.21166.
2. Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer, 127(12), 2893-2917. doi: 10.1002/ijc.25516.
3. Hidalgo, M. (2010). Pancreatic cancer. The New England Journal of Medicine, 362(17), 1605-1617. doi: 10.1056/NEJMra0901557.
4. Vincent, A., Herman, J., Schulick, R., Hruban, R. H., & Goggins, M. (2011). Pancreatic cancer. Lancet, 378(9791), 607-620. doi: 10.1016/S0140- 6736(10)62307-0.
5. Burris, H. A., 3rd, Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., et al. (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of Clinical Oncology, 15(6), 2403-2413.
6. Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., et al. (2007). Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 25(15), 1960-1966. doi: 10.1200/JCO.2006.07.9525.
7. Di Marco, M., Di Cicilia, R., Macchini, M., Nobili, E., Vecchiarelli, S., Brandi, G., et al. (2010). Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review). Oncology Reports, 23(5), 1183-1192.
8. Conroy, T., Desseigne, F., Ychou, M., Bouche, O., Guimbaud, R., Becouarn, Y., et al. (2011). FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. The New England Journal of Medicine, 364(19), 1817-1825. doi: 10.1056/NEJMoa1011923.
9. Duner, S., Lopatko Lindman, J., Ansari, D., Gundewar, C., & Andersson, R. (2010). Pancreatic cancer: the role of pancreatic stellate cells in tumor progression. Pancreatology, 10(6), 673-681. doi: 10.1159/000320711.
10. Garber, K. (2010). Stromal depletion goes on trial in pancreatic cancer. Journal of the National Cancer Institute, 102(7), 448-450. doi: 10.1093/jnci/djq113.
11. Von Hoff, D. D., Ervin, T. J., Arena, F. P., Chiorean, E. G., Infante, J. R., Moore, M. J., et al. (2012). Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). Journal of Clinical Oncology, 30(suppl 34), abstr LBA148.
12. Chiodoni, C., Colombo, M. P., & Sangaletti, S. (2010). Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis. Cancer and Metastasis Reviews, 29(2), 295-307. doi: 10.1007/s10555-010-9221-8.
13. Tai, I., Tai, I. T., & Tang, M. J. (2008). SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resistance Updates, 11(6), 231-246. doi: 10.1016/j.drup.2008.08.005 S1368-7646(08)00048-4.
14. Bradshaw, A. D., & Sage, E. H. (2001). SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. The Journal of Clinical Investigation, 107(9), 1049-1054. doi: 10.1172/JCI12939.
15. Bradshaw, A. D. (2012). Diverse biological functions of the SPARC family of proteins. The International Journal of Biochemistry & Cell Biology, 44(3), 480-488. doi: 10.1016/j.biocel.2011.12.021 S1357-2725(12)00004-0.
16. Swaroop, A., Hogan, B. L., & Francke, U. (1988). Molecular analysis of the cDNA for human SPARC/osteonectin/BM-40: sequence, expression, and localization of the gene to chromosome 5q31-q33. Genomics, 2(1), 37-47.
17. Nagaraju, G. P., & El-Rayes, B. F. (2013). SPARC and DNA methylation: possible diagnostic and therapeutic implications in gastrointestinal cancers. Cancer Letters, 328(1), 10-17. doi: 10.1016/j.canlet.2012.08.028.
18. Kaufmann, B., Muller, S., Hanisch, F. G., Hartmann, U., Paulsson, M., Maurer, P., et al. (2004). Structural variability of BM-40/SPARC/osteonectin glycosylation: implications for collagen affinity. Glycobiology, 14(7), 609-619. doi: 10.1093/glycob/cwh063 cwh063.
19. Motamed, K. (1999). SPARC (osteonectin/BM-40). The International Journal of Biochemistry & Cell Biology, 31(12), 1363-1366.
20. Chlenski, A., & Cohn, S. L. (2010). Modulation of matrix remodeling by SPARC in neoplastic progression. Seminars in Cell & Developmental Biology, 21(1), 55-65. doi: 10.1016/j.semcdb.2009.11.018 S1084-9521(09)00243-2.
21. Nagaraju, G. P., & Sharma, D. (2011). Anti-cancer role of SPARC, an inhibitor of adipogenesis. Cancer Treatment Reviews, 37(7), 559-566. doi: 10.1016/j.ctrv.2010.12.001 S0305-7372(10)00212-4.
22. Rahman, M., Chan, A. P., & Tai, I. T. (2011). A peptide of SPARC interferes with the interaction between caspase8 and Bcl2 to resensitize chemoresistant tumors and enhance their regression in vivo. PLoS One, 6(11), e26390. doi: 10.1371/journal.pone.0026390 PONE-D-11-11572.
23. Gilmour, D. T., Lyon, G. J., Carlton, M. B., Sanes, J. R., Cunningham, J. M., Anderson, J. R., et al. (1998). Mice deficient for the secreted glycoprotein SPARC/osteonectin/BM40 develop normally but show severe age-onset cataract formation and disruption of the lens. EMBO Journal, 17(7), 1860-1870. doi: 10.1093/emboj/17.7.1860.
24. Delany, A. M., Amling, M., Priemel, M., Howe, C., Baron, R., & Canalis, E. (2000). Osteopenia and decreased bone formation in osteonectin-deficient mice. The Journal of Clinical Investigation, 105(7), 915-923. doi: 10.1172/JCI7039.
25. Bradshaw, A. D., Puolakkainen, P., Dasgupta, J., Davidson, J. M., Wight, T. N., & Helene Sage, E. (2003). SPARC-null mice display abnormalities in the dermis characterized by decreased collagen fibril diameter and reduced tensile strength. Journal of Investigative Dermatology, 120(6), 949-955. doi: 10.1046/j.1523-1747.2003.12241.x.
26. Schellings, M. W., Vanhoutte, D., Swinnen, M., Cleutjens, J. P., Debets, J., van Leeuwen, R. E., et al. (2009). Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction. The Journal of Experimental Medicine, 206(1), 113-123. doi: 10.1084/jem.20081244 jem.20081244.
27. Bradshaw, A. D., Graves, D. C., Motamed, K., & Sage, E. H. (2003). SPARC-null mice exhibit increased adiposity without significant differences in overall body weight. Proceedings of the National Academy of Sciences of the United States of America, 100(10), 6045-6050. doi: 10.1073/pnas.1030790100 1030790100.
28. Shankavaram, U. T., DeWitt, D. L., Funk, S. E., Sage, E. H., & Wahl, L. M. (1997). Regulation of human monocyte matrix metalloproteinases by SPARC. Journal of Cellular Physiology, 173(3), 327-334. doi: 10.1002/(SICI)1097- 4652(199712)173:3<327::AID-JCP4>3.0.CO;2-P.
29. Tremble, P. M., Lane, T. F., Sage, E. H., & Werb, Z. (1993). SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway. The Journal of Cell Biology, 121(6), 1433-1444.
30. Rivera, L. B., Bradshaw, A. D., & Brekken, R. A. (2011). The regulatory function of SPARC in vascular biology. Cellular and Molecular Life Sciences, 68(19), 3165-3173. doi: 10.1007/s00018-011-0781-8.
31. Kupprion, C., Motamed, K., & Sage, E. H. (1998). SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. Journal of Biological Chemistry, 273(45), 29635-29640.
32. Raines, E. W., Lane, T. F., Iruela-Arispe, M. L., Ross, R., & Sage, E. H. (1992). The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. Proceedings of the National Academy of Sciences of the United States of America, 89(4), 1281-1285.
33. Motamed, K., Blake, D. J., Angello, J. C., Allen, B. L., Rapraeger, A. C., Hauschka, S. D., et al. (2003). Fibroblast growth factor receptor-1 mediates the inhibition of endothelial cell proliferation and the promotion of skeletal myoblast differentiation by SPARC: a role for protein kinase A. Journal of Cellular Biochemistry, 90(2), 408-423. doi: 10.1002/jcb.10645.
34. Hasselaar, P., & Sage, E. H. (1992). SPARC antagonizes the effect of basic fibroblast growth factor on the migration of bovine aortic endothelial cells. Journal of Cellular Biochemistry, 49(3), 272-283. doi: 10.1002/jcb.240490310.
35. Chlenski, A., Liu, S., Guerrero, L. J., Yang, Q., Tian, Y., Salwen, H. R., et al. (2006). SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix. International Journal of Cancer, 118(2), 310-316. doi: 10.1002/ijc.21357.
36. Wrana, J. L., Overall, C. M., & Sodek, J. (1991). Regulation of the expression of a secreted acidic protein rich in cysteine (SPARC) in human fibroblasts by transforming growth factor beta. Comparison of transcriptional and post-transcriptional control with fibronectin and type I collagen. European Journal of Biochemistry, 197(2), 519-528.
37. Francki, A., Bradshaw, A. D., Bassuk, J. A., Howe, C. C., Couser, W. G., & Sage, E. H. (1999). SPARC regulates the expression of collagen type I and transforming growth factor-beta1 in mesangial cells. Journal of Biological Chemistry, 274(45), 32145-32152.
38. Francki, A., McClure, T. D., Brekken, R. A., Motamed, K., Murri, C., Wang, T., et al. (2004). SPARC regulates TGF-beta1-dependent signaling in primary glomerular mesangial cells. Journal of Cellular Biochemistry, 91(5), 915-925. doi: 10.1002/jcb.20008.
39. Schiemann, B. J., Neil, J. R., & Schiemann, W. P. (2003). SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. Molecular Biology of the Cell, 14(10), 3977-3988. doi: 10.1091/mbc.E03-01-0001 E03-01-0001.
40. Chlenski, A., Guerrero, L. J., Yang, Q., Tian, Y., Peddinti, R., Salwen, H. R., et al. (2007). SPARC enhances tumor stroma formation and prevents fibroblast activation. Oncogene, 26(31), 4513-4522. doi: 10.1038/sj.onc.1210247.
41. Weaver, M. S., & Workman, G. (2008). The copper binding domain of SPARC mediates cell survival in vitro via interaction with integrin beta1 and activation of integrin-linked kinase. Journal of Biological Chemistry, 283(33), 22826-22837. doi: 10.1074/jbc.M706563200 M706563200.
42. Kelly, K. A., Allport, J. R., Yu, A. M., Sinh, S., Sage, E. H., Gerszten, R. E., et al. (2007). SPARC is a VCAM-1 counter-ligand that mediates leukocyte transmigration. Journal of Leukocyte Biology, 81(3), 748-756. doi: 10.1189/jlb.1105664.
43. Llera, A. S., Girotti, M. R., Benedetti, L. G., & Podhajcer, O. L. (2010). Matricellular proteins and inflammatory cells: a task force to promote or defeat cancer? Cytokine & Growth Factor Reviews, 21(1), 67-76. doi: 10.1016/j.cytogfr.2009.11.010 S1359-6101(09)00117-8.
44. Chong, H. C., Tan, C. K., Huang, R. L., & Tan, N. S. (2012). Matricellular proteins: a sticky affair with cancers. Journal of Oncology, 2012, 351089. doi: 10.1155/2012/351089.
45. Barker, T. H., Baneyx, G., Cardo-Vila, M., Workman, G. A., Weaver, M., Menon, P. M., et al. (2005). SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity. Journal of Biological Chemistry, 280(43), 36483-36493. doi: 10.1074/jbc.M504663200.
46. Podhajcer, O. L., Benedetti, L., Girotti, M. R., Prada, F., Salvatierra, E., & Llera, A. S. (2008). The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer and Metastasis Reviews, 27(3), 523-537. doi: 10.1007/s10555-008-9135-x.
47. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646-674. doi: 10.1016/j.cell.2011.02.013 S0092-8674(11)00127-9.
48. Yang, E., Kang, H. J., Koh, K. H., Rhee, H., Kim, N. K., & Kim, H. (2007). Frequent inactivation of SPARC by promoter hypermethylation in colon cancers. International Journal of Cancer, 121(3), 567-575. doi: 10.1002/ijc.22706.
49. Lussier, C., Sodek, J., & Beaulieu, J. F. (2001). Expression of SPARC/osteonectin/BM4O in the human gut: predominance in the stroma of the remodeling distal intestine. Journal of Cellular Biochemistry, 81(3), 463-476.
50. Tai, I. T., Dai, M., Owen, D. A., & Chen, L. B. (2005). Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. The Journal of Clinical Investigation, 115(6), 1492-1502. doi: 10.1172/JCI23002.
51. Cheetham, S., Tang, M. J., Mesak, F., Kennecke, H., Owen, D., & Tai, I. T. (2008). SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2'deoxycytidine to increase SPARC expression and improve therapy response. British Journal of Cancer, 98(11), 1810-1819. doi: 10.1038/sj.bjc.6604377.
52. Tang, M. J., & Tai, I. T. (2007). A novel interaction between procaspase 8 and SPARC enhances apoptosis and potentiates chemotherapy sensitivity in colorectal cancers. Journal of Biological Chemistry, 282(47), 34457-34467. doi: 10.1074/jbc.M704459200.
53. Chan, S. K., Griffith, O. L., Tai, I. T., & Jones, S. J. (2008). Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers. Cancer Epidemiology, Biomarkers & Prevention, 17(3), 543-552. doi: 10.1158/1055-9965.EPI-07-2615.
54. Socha, M. J., Said, N., Dai, Y., Kwong, J., Ramalingam, P., Trieu, V., et al. (2009). Aberrant promoter methylation of SPARC in ovarian cancer. Neoplasia, 11(2), 126-135.
55. Mok, S. C., Chan, W. Y., Wong, K. K., Muto, M. G., & Berkowitz, R. S. (1996). SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene, 12(9), 1895-1901.
56. Yiu, G. K., Chan, W. Y., Ng, S. W., Chan, P. S., Cheung, K. K., Berkowitz, R. S., et al. (2001). SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. American Journal of Pathology, 159(2), 609-622. doi: 10.1016/S0002-9440(10)61732-4.
57. Said, N., & Motamed, K. (2005). Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. American Journal of Pathology, 167(6), 1739-1752. doi: 10.1016/S0002-9440(10) 61255-2.
58. Said, N., Najwer, I., & Motamed, K. (2007). Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer. American Journal of Pathology, 170(3), 1054-1063. doi: 10.2353/ajpath.2007.060903.
59. Said, N. A., Elmarakby, A. A., Imig, J. D., Fulton, D. J., & Motamed, K. (2008). SPARC ameliorates ovarian cancer-associated inflammation. Neoplasia, 10(10), 1092-1104.
60. Said, N., Socha, M. J., Olearczyk, J. J., Elmarakby, A. A., Imig, J. D., & Motamed, K. (2007). Normalization of the ovarian cancer microenvironment by SPARC. Molecular Cancer Research, 5(10), 1015-1030. doi: 10.1158/1541-7786. MCR-07-0001.
61. Brown, T. J., Shaw, P. A., Karp, X., Huynh, M. H., Begley, H., & Ringuette, M. J. (1999). Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer. Gynecologic Oncology, 75(1), 25-33. doi: 10.1006/gyno.1999.5552.
62. Thomas, R., True, L. D., Bassuk, J. A., Lange, P. H., & Vessella, R. L. (2000). Differential expression of osteonectin/SPARC during human prostate cancer progression. Clinical Cancer Research, 6(3), 1140-1149.
63. Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., et al. (2001). Delineation of prognostic biomarkers in prostate cancer. Nature, 412(6849), 822-826. doi: 10.1038/35090585.
64. Wong, S. Y., Crowley, D., Bronson, R. T., & Hynes, R. O. (2008). Analyses of the role of endogenous SPARC in mouse models of prostate and breast cancer. Clinical & Experimental Metastasis, 25(2), 109-118. doi: 10.1007/s10585-007-9126-2.
65. Said, N., Frierson, H. F., Jr., Chernauskas, D., Conaway, M., Motamed, K., & Theodorescu, D. (2009). The role of SPARC in the TRAMP model of prostate carcinogenesis and progression. Oncogene, 28(39), 3487-3498. doi: 10.1038/onc.2009.205.
66. Chlenski, A., Liu, S., Crawford, S. E., Volpert, O. V., DeVries, G. H., Evangelista, A., et al. (2002). SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Research, 62(24), 7357-7363.
67. Chlenski, A., Liu, S., Baker, L. J., Yang, Q., Tian, Y., Salwen, H. R., et al. (2004). Neuroblastoma angiogenesis is inhibited with a folded synthetic molecule corresponding to the epidermal growth factor-like module of the follistatin domain of SPARC. Cancer Research, 64(20), 7420-7425. doi: 10.1158/0008-5472.CAN-04-2141.
68. Smid, M., Dorssers, L. C., & Jenster, G. (2003). Venn Mapping: clustering of heterologous microarray data based on the number of co-occurring differentially expressed genes. Bioinformatics, 19(16), 2065-2071.
69. Bergamaschi, A., Tagliabue, E., Sorlie, T., Naume, B., Triulzi, T., Orlandi, R., et al. (2008). Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. The Journal of Pathology, 214(3), 357-367. doi: 10.1002/path.2278.
70. Teschendorff, A. E., Miremadi, A., Pinder, S. E., Ellis, I. O., & Caldas, C. (2007). An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biology, 8(8), R157. doi: 10.1186/gb-2007-8-8-r157.
71. Dhanesuan, N., Sharp, J. A., Blick, T., Price, J. T., & Thompson, E. W. (2002). Doxycycline-inducible expression of SPARC/Osteonectin/BM40 in MDA-MB-231 human breast cancer cells results in growth inhibition. Breast Cancer Research and Treatment, 75(1), 73-85.
72. Koblinski, J. E., Kaplan-Singer, B. R., VanOsdol, S. J., Wu, M., Engbring, J. A., Wang, S., et al. (2005). Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis. Cancer Research, 65(16), 7370-7377. doi: 10.1158/0008-5472.CAN-05-0807.
73. Sangaletti, S., Stoppacciaro, A., Guiducci, C., Torrisi, M. R., & Colombo, M. P. (2003). Leukocyte, rather than tumor-produced SPARC, determines stroma and collagen type IV deposition in mammary carcinoma. The Journal of Experimental Medicine, 198(10), 1475-1485. doi: 10.1084/jem.20030202.
74. Bellahcene, A., & Castronovo, V. (1995). Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. American Journal of Pathology, 146(1), 95-100.
75. Barth, P. J., Moll, R., & Ramaswamy, A. (2005). Stromal remodeling and SPARC (secreted protein acid rich in cysteine) expression in invasive ductal carcinomas of the breast. Virchows Archiv, 446(5), 532-536. doi: 10.1007/s00428-005-1256-9.
76. Jones, C., Mackay, A., Grigoriadis, A., Cossu, A., Reis-Filho, J. S., Fulford, L., et al. (2004). Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Research, 64(9), 3037-3045.
77. Campo McKnight, D. A., Sosnoski, D. M., Koblinski, J. E., & Gay, C. V. (2006). Roles of osteonectin in the migration of breast cancer cells into bone. Journal of Cellular Biochemistry, 97(2), 288-302. doi: 10.1002/jcb.20644.
78. Briggs, J., Chamboredon, S., Castellazzi, M., Kerry, J. A., & Bos, T. J. (2002). Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells. Oncogene, 21(46), 7077-7091. doi: 10.1038/sj.onc.1205857.
79. Schultz, C., Lemke, N., Ge, S., Golembieski, W. A., & Rempel, S. A. (2002). Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. Cancer Research, 62(21), 6270-6277.
80. Yunker, C. K., Golembieski, W., Lemke, N., Schultz, C. R., Cazacu, S., Brodie, C., et al. (2008). SPARC-induced increase in glioma matrix and decrease in vascularity are associated with reduced VEGF expression and secretion. International Journal of Cancer, 122(12), 2735-2743. doi: 10.1002/ijc.23450.
81. Rempel, S. A., Golembieski, W. A., Ge, S., Lemke, N., Elisevich, K., Mikkelsen, T., et al. (1998). SPARC: a signal of astrocytic neoplastic transformation and reactive response in human primary and xenograft gliomas. Journal of Neuropathology and Experimental Neurology, 57(12), 1112-1121.
82. Shi, Q., Bao, S., Maxwell, J. A., Reese, E. D., Friedman, H. S., Bigner, D. D., et al. (2004). Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. Journal of Biological Chemistry, 279(50), 52200-52209. doi: 10.1074/jbc.M409630200.
83. Shi, Q., Bao, S., Song, L., Wu, Q., Bigner, D. D., Hjelmeland, A. B., et al. (2007). Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases. Oncogene, 26(28), 4084-4094. doi: 10.1038/sj.onc.1210181.
84. McClung, H. M., Thomas, S. L., Osenkowski, P., Toth, M., Menon, P., Raz, A., et al. (2007). SPARC upregulates MT1-MMP expression, MMP-2 activation, and the secretion and cleavage of galectin-3 in U87MG glioma cells. Neuroscience Letters, 419(2), 172-177. doi: 10.1016/j.neulet.2007.04.037.
85. Kunigal, S., Gondi, C. S., Gujrati, M., Lakka, S. S., Dinh, D. H., Olivero, W. C., et al. (2006). SPARC-induced migration of glioblastoma cell lines via uPA-uPAR signaling and activation of small GTPase RhoA. International Journal of Oncology, 29(6), 1349-1357.
86. Golembieski, W. A., Thomas, S. L., Schultz, C. R., Yunker, C. K., McClung, H. M., Lemke, N., et al. (2008). HSP27 mediates SPARC-induced changes in glioma morphology, migration, and invasion. GLIA, 56(10), 1061-1075. doi: 10.1002/glia.20679.
87. Prada, F., Benedetti, L. G., Bravo, A. I., Alvarez, M. J., Carbone, C., & Podhajcer, O. L. (2007). SPARC endogenous level, rather than fibroblast-produced SPARC or stroma reorganization induced by SPARC, is responsible for melanoma cell growth. The Journal of Investigative Dermatology, 127(11), 2618-2628. doi: 10.1038/sj.jid.5700962.
88. Haber, C. L., Gottifredi, V., Llera, A. S., Salvatierra, E., Prada, F., Alonso, L., et al. (2008). SPARC modulates the proliferation of stromal but not melanoma cells unless endogenous SPARC expression is downregulated. International Journal of Cancer, 122(7), 1465-1475. doi: 10.1002/ijc.23216.
89. Ledda, F., Bravo, A. I., Adris, S., Bover, L., Mordoh, J., & Podhajcer, O. L. (1997). The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. The Journal of Investigative Dermatology, 108(2), 210-214.
90. Massi, D., Franchi, A., Borgognoni, L., Reali, U. M., & Santucci, M. (1999). Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Human Pathology, 30(3), 339-344.
91. Alonso, S. R., Tracey, L., Ortiz, P., Perez-Gomez, B., Palacios, J., Pollan, M., et al. (2007). A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Research, 67(7), 3450-3460. doi: 10.1158/0008-5472.CAN-06-3481.
92. Ledda, M. F., Adris, S., Bravo, A. I., Kairiyama, C., Bover, L., Chernajovsky, Y., et al. (1997). Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nature Medicine, 3(2), 171-176.
93. Alvarez, M. J., Prada, F., Salvatierra, E., Bravo, A. I., Lutzky, V. P., Carbone, C., et al. (2005). Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity. Cancer Research, 65(12), 5123-5132. doi: 10.1158/0008-5472.CAN-04-1102.
94. Von Hoff, D. D., Penny, R., Shack, S., Campbell, E., Taverna, D., Borad, M., et al. (2006). Frequency of potential therapeutic targets identified by immunochemistry (IHC) and DNA microarray (DMA) in tumors from patients who have progressed on multiple therapeutic agents. Journal of Clinical Oncology, 24(18S), abstr 3071.
95. Guweidhi, A., Kleeff, J., Adwan, H., Giese, N. A., Wente, M. N., Giese, T., et al. (2005). Osteonectin influences growth and invasion of pancreatic cancer cells. Annals of Surgery, 242(2), 224-234.
96. Miyoshi, K., Sato, N., Ohuchida, K., Mizumoto, K., & Tanaka, M. (2010). SPARC mRNA expression as a prognostic marker for pancreatic adenocarcinoma patients. Anticancer Research, 30(3), 867-871.
97. Prenzel, K. L., Warnecke-Eberz, U., Xi, H., Brabender, J., Baldus, S. E., Bollschweiler, E., et al. (2006). Significant overexpression of SPARC/osteonectin mRNA in pancreatic cancer compared to cancer of the papilla of Vater. Oncology Reports, 15(5), 1397-1401.
98. Infante, J. R., Matsubayashi, H., Sato, N., Tonascia, J., Klein, A. P., Riall, T. A., et al. (2007). Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. Journal of Clinical Oncology, 25(3), 319-325. doi: 10.1200/JCO.2006.07.8824.
99. Mantoni, T. S., Schendel, R. R., Rodel, F., Niedobitek, G., Al-Assar, O., Masamune, A., et al. (2008). Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma. Cancer Biology & Therapy, 7(11), 1806-1815.
100. Sato, N., Fukushima, N., Maehara, N., Matsubayashi, H., Koopmann, J., Su, G. H., et al. (2003). SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene, 22(32), 5021-5030. doi: 10.1038/sj.onc.1206807.
101. Gao, J., Song, J., Huang, H., Li, Z., Du, Y., Cao, J., et al. (2010). Methylation of the SPARC gene promoter and its clinical implication in pancreatic cancer. Journal of Experimental & Clinical Cancer Research, 29, 28. doi: 10.1186/1756-9966-29-28.
102. Nagaraju, G. P., & Ei-Rayes, B. F. (2013). SPARC and DNA methylation: possible diagnostic and therapeutic implications in gastrointestinal cancers. Cancer Letters, 328(1), 10-17. doi: 10.1016/j.canlet.2012.08.028S0304-3835(12) 00516-2.
103. Chen, G., Tian, X., Liu, Z., Zhou, S., Schmidt, B., Henne-Bruns, D., et al. (2010). Inhibition of endogenous SPARC enhances pancreatic cancer cell growth: modulation by FGFR1-III isoform expression. British Journal of Cancer, 102(1), 188-195. doi: 10.1038/sj.bjc.66054406605440.
104. Zhivkova-Galunska, M., Adwan, H., Eyol, E., Kleeff, J., Kolb, A., Bergmann, F., et al. (2010). Osteopontin but not osteonectin favors the metastatic growth of pancreatic cancer cell lines. Cancer Biology & Therapy, 10(1), 54-64.
105. Puolakkainen, P. A., Brekken, R. A., Muneer, S., & Sage, E. H. (2004). Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Molecular Cancer Research, 2(4), 215-224.
106. Arnold, S., Mira, E., Muneer, S., Korpanty, G., Beck, A. W., Holloway, S. E., et al. (2008). Forced expression of MMP9 rescues the loss of angiogenesis and abrogates metastasis of pancreatic tumors triggered by the absence of host SPARC. Experimental Biology and Medicine (Maywood, N.J.), 233(7), 860-873. doi: 10.3181/0801-RM-12 0801-RM-12.
107. Arnold, S. A., Rivera, L. B., Miller, A. F., Carbon, J. G., Dineen, S. P., Xie, Y., et al. (2010). Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma. Disease Models & Mechanisms, 3(1-2), 57-72. doi: 10.1242/dmm.003228 dmm.003228.
108. Rivera, L. B., & Brekken, R. A. (2011). SPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF-beta1 activity. The Journal of Cell Biology, 193(7), 1305-1319. doi: 10.1083/jcb.201011143.
109. Arnold, S. A., Rivera, L. B., Carbon, J. G., Toombs, J. E., Chang, C. L., Bradshaw, A. D., et al. (2012). Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFbeta activation. PLoS One, 7(2), e31384. doi: 10.1371/journal.pone.0031384 PONE-D-11-19108.
110. Rempel, S. A., Hawley, R. C., Gutierrez, J. A., Mouzon, E., Bobbitt, K. R., Lemke, N., et al. (2007). Splenic and immune alterations of the Sparc-null mouse accompany a lack of immune response. Genes and Immunity, 8(3), 262-274. doi: 10.1038/sj.gene.6364388.
111. Gradishar, W. J. (2006). Albumin-bound paclitaxel: a next-generation taxane. Expert Opinion on Pharmacotherapy, 7(8), 1041-1053. doi: 10.1517/14656566.7.8.1041.
112. Guarneri, V., Dieci, M. V., & Conte, P. (2012). Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. Expert Opinion on Pharmacotherapy, 13(3), 395-406. doi: 10.1517/14656566.2012.651127.
113. Schilling, U., Friedrich, E. A., Sinn, H., Schrenk, H. H., Clorius, J. H., & Maier-Borst, W. (1992). Design of compounds having enhanced tumour uptake, using serum albumin as a carrier - part II. In vivo studies. International Journal of Radiation Applications and Instrumentation. Part B, 19(6), 685-695.
114. Minshall, R. D., Tiruppathi, C., Vogel, S. M., & Malik, A. B. (2002). Vesicle formation and trafficking in endothelial cells and regulation of endothelial barrier function. Histochemistry and Cell Biology, 117(2), 105-112. doi: 10.1007/s00418-001-0367-x.
115. Desai, N., Trieu, V., Damascelli, B., & Soon-Shiong, P. (2009). SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Translational Oncology, 2(2), 59-64.
116. Ibrahim, N. K., Desai, N., Legha, S., Soon-Shiong, P., Theriault, R. L., Rivera, E., et al. (2002). Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clinical Cancer Research, 8(5), 1038-1044.
117. Belli, C., Cereda, S., & Reni, M. (2012). Role of taxanes in pancreatic cancer. World Journal of Gastroenterology, 18(33), 4457-4465. doi: 10.3748/wjg.v18.i33.4457.
118. Fine, R. L., Fogelman, D. R., Schreibman, S. M., Desai, M., Sherman, W., Strauss, J., et al. (2008). The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemotherapy and Pharmacology, 61(1), 167-175. doi: 10.1007/s00280-007-0473-0.
119. Reni, M., Cereda, S., Rognone, A., Belli, C., Ghidini, M., Longoni, S., et al. (2012). A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). Cancer Chemotherapy and Pharmacology, 69(1), 115-123. doi: 10.1007/s00280-011-1680-2.
120. Von Hoff, D. D., Ramanathan, R. K., Borad, M. J., Laheru, D. A., Smith, L. S., Wood, T. E., et al. (2011). Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. Journal of Clinical Oncology, 29(34), 4548-4554. doi: 10.1200/JCO.2011.36.5742JCO.2011. 36.5742.
121. Hosein, P. J., de Lima Lopes, G., Jr., Pastorini, V. H., Gomez, C., Macintyre, J., Zayas, G., et al. (2012). A phase II trial of nab-paclitaxel as second-line therapy in patients with advanced pancreatic cancer. American Journal of Clinical Oncology. doi: 10.1097/COC.0b013e3182436e8c.
122. Awasthi, N., Ostapoff, K., Zhang, C., Schwarz, M. A., & Schwarz, R. E. (2012). Evaluation of combination treatment benefits of nab-paclitaxel in experimental pancreatic cancer. Journal of Clinical Oncology, 30(suppl 4), abstr 170.
123. Frese, K. K., Neesse, A., Cook, N., Bapiro, T. E., Lolkema, M. P., Jodrell, D. I., et al. (2012). nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discovery, 2(3), 260-269. doi: 10.1158/2159-8290.CD-11-0242.